A Phase 3 interventional study of Levonorgestrel/Ethinyl Estradiol in Premenstrual Syndrome, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed at 48 sites in United States. Open to female participants aged 18 Years to 49 Years. Per ClinicalTrials.gov, last updated 2013-02-08.
Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Premenstrual Syndrome with a site in United States — 6 open to participants now, 6 under way, none of them phase 3. Premenstrual Syndrome · United States.
Among the 36 studies in Premenstrual Syndrome with a site in United States, this one is the 4th largest by enrollment of the 31 interventional ones that give a count, is one of 2 that started in 2005, is one of 3 in phase 3, and was the 9th registered.
177 studies on the registry are indexed under Premenstrual Syndrome; 32 are open to participants now.
Browse Premenstrual Syndrome studies →6 of the 36 studies in Premenstrual Syndrome with a site in United States are open now. Recruiting first, the newest first:
Vivance Group · Sites in United States
Ages 18–45 · Women only · Healthy volunteers
Samphire Group, Inc. · Sites in United States
Ages 18–65 · Women only · Healthy volunteers
Johns Hopkins University · Sites in United States
Ages 18–50 · Women only · Healthy volunteers
University of Colorado, Colorado Springs · Sites in United States
Ages 18–40 · Women only
Johns Hopkins University · Sites in United States
Ages 18–50 · Women only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 12 Premenstrual Syndrome studies recruiting now, none (0%) set no upper age limit and 12 (100%) stop at 75 or younger; none take children under 18; 10 take healthy volunteers.
This study: 18 Years to 49 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 4 · Phase 3 5 · Phase 4 7
First in 1984; this study’s year is marked. 2 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 200 is above the median of 70 across 154 interventional studies indexed under Premenstrual Syndrome.
Median enrollment 40 across the 31 interventional studies, 275 across the 4 observational. Of the 29 that completed or were terminated, 9 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 36 have an industry lead sponsor. The 10 most frequent:
This study is registered under Wyeth is now a wholly owned subsidiary of Pfizer, one of the names counted as Pfizer. Under that name alone:
Wyeth is now a wholly owned subsidiary of Pfizer is the lead sponsor of 484 studies on the registry; none are open to participants now.
Pfizer has 3 studies filed under Premenstrual Syndrome — fewer than ten, so there is no comparison to draw.
2 of the studies in Premenstrual Syndrome with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07876050Vivance GroupA Clinical Trial to Evaluate the Effects of the Kaia Relief - Cycle System on Premenstrual Symptom Severity, Menstrual Discomfort, and Overall Well-Being in Premenopausal Women. | 2027-01 |
| NCT07679074Samphire Group, Inc.CREST: Samphire Guided Care Program on Wellbeing, Work Productivity, and Quality of Life | 2027-01-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 36 studies in Premenstrual Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether LNG/EE is effective in the treatment of menstrual cycle related symptoms.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug pages: Levonorgestrel · Ethinyl Estradiol
To evaluate the efficacy of a continuous-use OC regimen containing a combination of LNG/EE in preventing moderate to severe cycle-related symptoms compared with placebo
To evaluate the effects of this LNG/EE regimen on work productivity and subject satisfaction in subjects with moderate to severe cycle-related symptoms at baseline compared with placebo
The record gives a start of Jul 2005, a primary completion of Aug 2006 and a completion of Aug 2006. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2007. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Levonorgestrel · Ethinyl Estradiol
Wyeth is now a wholly owned subsidiary of Pfizer →